Clinical Trial: Evaluating Pharmacokinetic and Safety of Saroglitazar Magnesium 1 Mg When Dosed on Alternate Days in Subjects Having Moderate Hepatic Impairment with Cirrhosis Due to Cholestatic Liver Disease

U.S., Feb. 14 -- ClinicalTrials.gov registry received information related to the study (NCT06825559) titled 'Evaluating Pharmacokinetic and Safety of Saroglitazar Magnesium 1 Mg When Dosed on Alternate Days in Subjects Having Moderate Hepatic Impairment with Cirrhosis Due to Cholestatic Liver Disease' on Feb. 09.

Brief Summary: Evaluating Pharmacokinetic and safety of Saroglitazar Magnesium 1 mg when dosed on alternate days in subjects having moderate hepatic impairment with cirrhosis due to cholestatic liver disease

Study Start Date: March 31

Study Type: INTERVENTIONAL

Condition: Cholestatic Liver Disease

Intervention: DRUG: Saroglitazar Magnesium 1 mg

Saroglitazar Magnesium 1 mg will be assigned to all participants enrolled in thi...